Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.

Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, Ancukiewicz M, Boucher Y, Jain RK, Xu L.

Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16618-23. doi: 10.1073/pnas.1117610109.

2.

Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.

Ganapathy V, Ge R, Grazioli A, Xie W, Banach-Petrosky W, Kang Y, Lonning S, McPherson J, Yingling JM, Biswas S, Mundy GR, Reiss M.

Mol Cancer. 2010 May 26;9:122. doi: 10.1186/1476-4598-9-122.

3.

An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.

Rausch MP, Hahn T, Ramanathapuram L, Bradley-Dunlop D, Mahadevan D, Mercado-Pimentel ME, Runyan RB, Besselsen DG, Zhang X, Cheung HK, Lee WC, Ling LE, Akporiaye ET.

Anticancer Res. 2009 Jun;29(6):2099-109.

4.

An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition.

Park CY, Min KN, Son JY, Park SY, Nam JS, Kim DK, Sheen YY.

Cancer Lett. 2014 Aug 28;351(1):72-80. doi: 10.1016/j.canlet.2014.05.006.

PMID:
24887560
5.

Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines.

Xu CC, Wu LM, Sun W, Zhang N, Chen WS, Fu XN.

Mol Med Rep. 2011 Sep-Oct;4(5):1007-15. doi: 10.3892/mmr.2011.530.

PMID:
21725601
6.

Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor.

Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun LZ.

Cancer Res. 2006 Jul 1;66(13):6714-21.

7.

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.

Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, Massagué J, Mundy GR, Guise TA.

J Clin Invest. 1999 Jan;103(2):197-206.

8.

Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.

Du S, Bouquet S, Lo CH, Pellicciotta I, Bolourchi S, Parry R, Barcellos-Hoff MH.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):91-9. doi: 10.1016/j.ijrobp.2014.09.026.

PMID:
25835621
9.
10.

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases.

Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL.

J Clin Invest. 2002 Jun;109(12):1551-9.

11.
12.

In vivo inhibition of bone morphogenetic protein-2 on breast cancer cell growth.

Ye S, Park BH, Song KJ, Kim JR, Jang KY, Park HS, Bae JS, Brochmann EJ, Wang JC, Murray SS, Lee KB.

Spine (Phila Pa 1976). 2013 Feb 1;38(3):E143-50. doi: 10.1097/BRS.0b013e31827db4c6.

PMID:
23169070
13.

The role of transforming growth factor-beta in suppression of hepatic metastasis from colon cancer.

Are C, Simms N, Rajput A, Brattain M.

HPB (Oxford). 2010 Sep;12(7):498-506. doi: 10.1111/j.1477-2574.2010.00219.x. Erratum in: HPB (Oxford). 2011 Aug;13(8):593. Rajupt, Ashwani [corrected to Rajput, Ashwani].

14.

Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.

Bandyopadhyay A, López-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ.

Cancer Res. 2002 Aug 15;62(16):4690-5.

15.

c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.

Kiyono K, Suzuki HI, Morishita Y, Komuro A, Iwata C, Yashiro M, Hirakawa K, Kano MR, Miyazono K.

Cancer Sci. 2009 Oct;100(10):1809-16. doi: 10.1111/j.1349-7006.2009.01248.x.

16.

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Jaeger-Lansky A, Cejka D, Ying L, Preusser M, Hoeflmayer D, Fuereder T, Koehrer S, Wacheck V.

Cancer Biol Ther. 2010 Jun 1;9(11):919-27.

PMID:
20404549
17.

Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.

Kang Y, Prentice MA, Mariano JM, Davarya S, Linnoila RI, Moody TW, Wakefield LM, Jakowlew SB.

Exp Lung Res. 2000 Dec;26(8):685-707.

PMID:
11195465
18.

TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL.

J Clin Invest. 2013 Mar;123(3):1348-58. doi: 10.1172/JCI65416.

19.
20.

Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.

Schniewind B, Groth S, Sebens Müerköster S, Sipos B, Schäfer H, Kalthoff H, Fändrich F, Ungefroren H.

Oncogene. 2007 Jul 19;26(33):4850-62.

PMID:
17297450
Items per page

Supplemental Content

Support Center